Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $21.90 USD
Change Today +0.40 / 1.86%
Volume 377.5K
EPZM On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 3:56 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

epizyme inc (EPZM) Snapshot

Open
$21.72
Previous Close
$21.50
Day High
$22.65
Day Low
$21.10
52 Week High
08/14/14 - $40.98
52 Week Low
05/1/15 - $15.51
Market Cap
899.9M
Average Volume 10 Days
422.2K
EPS TTM
$-3.17
Shares Outstanding
41.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EPIZYME INC (EPZM)

epizyme inc (EPZM) Related Businessweek News

No Related Businessweek News Found

epizyme inc (EPZM) Details

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops epigenetic therapies for cancer patients. Its proprietary product platform creates small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases (HMTs). The company has two HMTs inhibitors in clinical development for the treatment of patients with cancers. It is conducting a Phase II clinical trial of tazemetostat (EPZ-6438), an inhibitor that targets the EZH2 HMT for the treatment of non-Hodgkin lymphoma and INI1-deficient solid tumors; and two Phase I clinical trials of pinometostat (EPZ-5676), an inhibitor targeting the DOT1L HMT for the treatment of acute leukemia with genetic alterations of the MLL gene. It has therapeutic collaborations with Celgene Corporation and Celgene International Sàrl; Eisai Co., Ltd.; and Glaxo Group Limited., as well as companion diagnostic development collaborations with Roche Molecular Systems, Inc. and Abbott Molecular Inc. Epizyme, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.

86 Employees
Last Reported Date: 03/12/15
Founded in 2007

epizyme inc (EPZM) Top Compensated Officers

Chief Executive Officer, President, Secretary...
Total Annual Compensation: $652.8K
Chief Scientific Officer and President of Res...
Total Annual Compensation: $531.7K
Chief Development Officer
Total Annual Compensation: $163.7K
Compensation as of Fiscal Year 2014.

epizyme inc (EPZM) Key Developments

Epizyme Provides Update on Tazemetostat (EPZ-6438)

Epizyme, Inc. announced that it has dosed the first patient in the phase 2 trial of its lead clinical candidate, tazemetostat (EPZ-6438) in patients with relapsed or refractory non-Hodgkin lymphoma (NHL). This five-arm study will enroll up to 150 patients with germinal center diffuse large B cell lymphoma (DLBCL) or follicular lymphoma, stratified into those expressing mutant EZH2 and those expressing wild type EZH2, as well as patients with non-germinal center DLBCL.

Epizyme, Inc. - Special Call

To discuss agreement with Celgene Corporation to extend the research collaboration between the two companies and to provide corporate update

Epizyme, Inc. Announces Extension of Celgene Corporation Research Collaboration

Epizyme, Inc. announced that it has amended and restated its agreement with Celgene Corporation to extend the research collaboration between the two companies for at least three additional years. Under the collaboration, Celgene will have the option to license histone methyltransferase (HMT) inhibitors being developed by Epizyme against three predefined targets. Under the terms of the revised agreement: Epizyme will receive a $10 million extension fee from Celgene in return for an option to individually license global rights for two of the targets and ex-US rights for the third target. Celgene may exercise its option with respect to each of the targets at the time of the IND filing for an additional pre-specified license payment. Epizyme will be responsible for leading and funding development for each target candidate through phase 1 clinical trials. Following the completion of phase 1, if Celgene chooses to continue its license for a specific target, it may do so by making an additional pre-specified payment. Epizyme may earn total potential milestones of up to $610 million on the three targets, including up to $75 million in development milestones and license fees, $365 million in regulatory milestones, and $170 million in sales milestones. Epizyme also may earn a royalty of up to a low double-digit percentage on worldwide net sales for two of the product candidates, and on ex-US net sales for the third product candidate. Epizyme will retain global rights to the remainder of its pipeline, as Celgene’s option to license ex-US rights for any other preclinical programs will terminate. In addition, Celgene will retain its ex-US license to, and the companies will continue their ongoing clinical collaboration on, pinometostat (EPZ-5676), a HMT inhibitor targeting DOT1L. Pinometostat is in phase 1 development for the treatment of patients with acute leukemia with alterations in the MLL gene (MLL-r).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EPZM:US $21.90 USD +0.40

EPZM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EPZM.
View Industry Companies
 

Industry Analysis

EPZM

Industry Average

Valuation EPZM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 26.0x
Price/Book 4.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 22.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EPIZYME INC, please visit www.epizyme.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.